Latest Revenue Growth News

Gryphon Capital Income Trust (ASX, GCI) reported a robust fiscal 2025 with a 41.65% jump in revenue and a substantial capital raise to expand its RMBS/ABS portfolio. The Trust’s net assets topped $1 billion, reflecting strong investor confidence and strategic growth.

Shriro Holdings reported a 5.5% beat on EBITDA guidance despite a 13.6% revenue decline driven by strategic shifts in its importer model and distributor consolidation. The company signals optimism for FY26 with new product launches and a capital-light growth strategy.

Australian Unity Limited reported robust FY2025 financial results, driven by strategic acquisitions and ongoing transformation efforts, returning to profitability with a $26.6 million net profit. The company is poised to complete its multi-year transformation by year-end and focus on growth amid rising demand for aged care and health services.

Nido Education Limited reported an 8% rise in Service EBITDA to $12.8 million for the first half of 2025, maintaining steady operational performance despite sector-wide occupancy challenges. The company declared a fully franked interim dividend of 1.5 cents per share, underscoring confidence in its growth strategy.

Nido Education Limited reported a 7.5% increase in revenue for the half-year ending June 2025, alongside a modest net profit and a fully franked interim dividend. The company also completed a strategic acquisition to expand its childcare footprint.

GenusPlus Group Ltd has delivered record FY2025 financial results, driven by strong contract wins and strategic acquisitions, positioning itself as a key player in Australia’s energy transition. The company forecasts robust earnings growth for FY2026 backed by a $2 billion orderbook.

GenusPlus Group has delivered a standout FY2025 with record revenue and profits, underpinned by strategic acquisitions and a booming renewable energy pipeline.

GenusPlus Group Ltd has reported a robust 36% increase in revenue and an 84% surge in net profit for FY2025, driven by strategic acquisitions and growth in the renewable energy sector. The company also declared a higher fully franked dividend, reflecting confidence in its expanding infrastructure footprint.

Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.

Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.

Enlitic, Inc. reported a sharp revenue increase driven by migration services and subscription growth, while sustaining a net loss of US$6.86 million in H1 2025. The company secured a binding MOU with GE Healthcare and completed a A$10 million capital raise.

Nova Eye Medical has delivered solid FY25 results, meeting sales guidance outside China and achieving six consecutive halves of growth in the US market. The company also improved gross margins and reduced cash burn, setting an optimistic tone for FY26 with breakeven EBITDA guidance.